Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
abducens nerve paralysis
acetylcholine receptor antibody
acoustic nerve
advances in neurology
adverse drug reaction
afebrile
agitation
anti GQ1b IgG antibody
antiviral agents
aphasia
areflexia
arteritides
arteritis, temporal
arteritis, temporal, recurrent
arthralgia
ataxia, sensory
atezolizumab
atypical
autoantibodies
autoimmune disease
autonomic dysfunction
B cell lymphoma
brain biopsy
Broca's aphasia
burning paresthesia
cancer associated myopathy
carcinoma
carcinoma of lung
cardiotoxicity
CAT scan, emission, abnormal
cauda equina
cauda equina, enhancement
cauda equina, lesion of
CD19-directed chimeric antigen receptor T-cell therapy
cerebellitis
cerebellitis, autoimmune
cerebral arteries
cerebrovascular accident
chemotherapy, CNS treatment and complications with
chorea
coinfection
complications
confusion
confusional state, acute
cranial nerve palsies
cranial neuropathy
cranial neuropathy, multiple
creatine phosphokinase(CPK)elevated
cytokine release syndrome
dabrafenib
demyelinating disease
dentate nuclei
dentate nuclei, lesion of
diabetes insipidus
differential diagnosis
diplopia
disorientation
dropped head syndrome
drug abuse
drug induced neurologic disorders
duvalumab
dyspnea
efficacy
electroencephalogram, abnormalities of
electromyogram
encephalitis
encephalitis, autoimmune
encephalitis, viral
encephalopathy
encephalopathy, acute
episodic disorders
extralimbic encephalitis
face, numbness of
facial nerve palsy
fever
Fisher's syndrome
gammaglobulin therapy, intravenous
ganglionitis
glutamic acid decarboxylase, antibody
granulomatous hypophysitis
Guillain Barre syndrome
hallucination
hallucination, auditory
hallucination, visual
headache
hemiparesis
hemiplegia, progressive
hippocampal atrophy
hippocampus, hyperintense
Hodgkin's disease
human herpesvirus 6
hyperactivity
hypercalcemia
iatrogenic neurologic disorders
idiopathic
immune checkpoint inhibitors
immune effector cell-associated neurotoxicity syndrome
immune-related adverse events
immunologic disease
immunomodulation
immunosuppression
immunosuppressive agents
immunotherapy
incidence
internal carotid artery
ipilimumab
JC virus
leukopenia
levamisole
limb-girdle weakness
limbic encephalitis
limbic system
lymph node biopsy
lymphadenopathy
lymphoma
lymphoma, systemic
melanoma, malignant
memory, impairment of
meningismus
meningitis
meningitis, drug induced
meningoencephalitis
mental status, abnormal
mesial temporal lobe
middle cerebral artery
misdiagnosis
monoclonal antibodies
mortality
MRI, abnormal
MRI, angiography
MRI, contrast enhanced
MRI, diffusion weighted
MRI, FLAIR
MRI, optic nerve
multiple organ failure
multiple sclerosis
muscle biopsy
muscle pain
muscle weakness
muscle weakness, proximal
myasthenia gravis
myasthenia gravis, drug induced
myasthenia gravis, unmasked
myocarditis
myopathy
myopathy, inflammatory
myopathy, necrotizing
myopathy, necrotizing, immune-mediated
myositis
nausea and vomiting
neck weakness
neoplasm, metastatic
neoplasm, metastatic to CNS
neoplasm, metastatic to CNS-treatment of
neurologic complications of, systemic cancer
neurologic complications of, systemic disease
neurologic disease
neurologic disease, diagnoses of
neurologic disease, multiple
neuromuscular junction
neuromuscular junction, abnormality of
neuronopathy, sensory
neuroophthalmology
neuropathy
neuropathy, iatrogenic
neuropathy, medication induced
neuropathy, sensory
neurotoxic
nivolumab
ocular motility, disorders of
ophthalmoplegia
opportunistic infection
opportunistic infection, CNS
optic disc edema
optic nerve, enhancement
optic neuritis
optic neuropathy
orthostatic hypotension
paraneoplastic ganglionopathy
paresthesias
pembrolizumab
pituitary stalk
pituitary stalk, enlarged
plasmapheresis
pleocytosis of cerebrospinal fluid
polymerase chain reaction, false negative
polyneuropathy, chronic inflammatory demyelinating
precipitating factors
prognosis
progressive multifocal leucoencephalopathy
progressive neurologic disorder
pruritus
pseudoathetosis
ptosis
ptosis, bilateral
radiation therapy, CNS treatment and complications with
rechallenge
recurrent
remote effect of cancer on the nervous system
respiratory failure
review article
rhabdomyolysis
risk factors
Romberg's sign
safety
sarcoidosis
sarcoidosis, CNS
seizure
sensory ganglia
sensory ganglia, abnormal
sensory loss
sensory loss, truncal
seronegative
Sjogren's syndrome
speech disorder
speech, slowed
steroid
steroid therapy, CNS treatment and complications with
systemic illness
temporal lobe, lesion
temporal lobe, lesion, bilateral
trametinib
treatment of neurologic disorder
tumor necrosis factor inhibitor
vasculitides
viral infection, CNS
visual acuity, decreased
visual loss
weakness
weakness, fatiguable
white matter disease
word-finding difficulty
workup
Showing articles 200 to 250 of 865 << Previous Next >>

FDA Approves Praxbind, the First Reversal Agent for the Anticoagulant Pradaxa
JAMA 314:2227, , 2015

Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Monoamine Oxidase Inhibitors
Adams & Victors Principles of Neurology Chp 43, pg 1210, Ropper, A.H.,et al, 2014

Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Serotonin Reuptake Inhibitors and Related Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1212, Ropper, A.H.,et al, 2014

Disturbances of Cerebrospinal Fluid, Including Hydrocephalus, Pseudotumor Cerebri, and Low-Pressure Syndromes, Pseudotumor Cerebri
Adams & Victors Principles of Neurology, Chp 30, pg 628, Ropper, A.H.,et al, 2014

Infections of the Nervous System, (Bacterial, Fungal, Spirochetal, Parasitic) and Sarcoidosis, Sarcoidosis
Adams & Victors Principles of Neurology, Chp 32, pg 721, Ropper, A.H.,et al, 2014

Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014

Association of Cerebral Microbleeds with Mortality in Stroke Patients Having Atrial Fibrillation
Neurol 83:1308-1315,1304, Song, T.J.,et al, 2014

Prosopometamorphopsia and Facial Hallucinations
Lancet 384:1998, Blom, J.D.,et al, 2014

Oral Anticoagulants and the Risk of Intracranial Hemorrhage
JAMA 312:2562-2563, Vespa, P.M., 2014

Mystery Case: A 63-year-old Man with Progressive Proximal Pain and Weakness
Neurol 82:e26-e29, Scripko, P.D.,et al, 2014

Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014

Bevacizumab in Glioblastoma - Still Much to Learn
NEJM 370:764-765, Fine, H.A., 2014

Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014

Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014

Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014

Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014

Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014

Subdural Haematoma in the Elderly
BMJ 348:g1682, Teale, E.A.,et al, 2014

Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014

Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014

Rethinking Warfarin for Atrial Fibrillation
JAMA 311:1246, Zuccott, G & Pflomm, J.M., 2014

Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014

Treatment of Primary CNS Vasculitis with Rituximab: Case Report
Neurol 82:1287-1288, Salvarani, C.,et al, 2014

Obsessive-Compulsive Disorder
BMJ 348:g2183, Veale, D.,et al, 2014

Fibromyalgia
JAMA 311:1547-1555, Clauw, D.J., 2014

Anti-HMGCR Autoantibodies in European Patients with Autoimmune Necrotizing Myopathies
Medicine 93:150-157, Allenbach, Y.,et al, 2014

Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014

Inhibition of Serotonin Reuptake by Antidepressants and Cerebral Microbleeds in the General Population
Stroke 45:1951-1957, Aarts, N.,et al, 2014

Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014

Novel Factor Xa Inhibitor for the Treatment of Cerebral Venous and Sinus Thrombosis
Stroke 45:2469-2471, Geisbusch, C.,et al, 2014

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated with Dabigatran or Warfarin
Stroke 45:2286-2291, Alonso, A.,et al, 2014

Cerebrovascular Events in 21 105 Patients with Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Stroke 45:2372-2378, Giugliano, R.P.,et al, 2014

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
JAMA Neurol 71:954-960, Clerico, M.,et al, 2014

The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013

Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013

Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013

Tumor Necrosis Factor-Alpha Inhibitors: Risk of Malignancy
UpToDate January, Stone, J.H., 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013

Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013

Statin Therapy should not be Discontinued in Patients with Intracerebral Hemorrhage
Stroke 44:2060-2061,2062, Bustamante, A. & Montaner, J., 2013

Statin Therapy should be Discontinued in Patients with Intracerebral Hemorrhage
Stroke 44:2058-2059,2062, Goldstein, L., 2013

Sarcoidosis Presenting as Longitudinally Extensive Myelitis
Neurol 81:e61, Goenka, N. & Venna N., 2013

Aggressive Medical Therapy Alone is Not Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2955-2956, Brown, M.M., 2013

Aggressive Medical Therapy Alone is Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2957-2958, Chaturvedi, S.,et al, 2013

Reduction in Early Stroke Risk in Carotid Stenosis with Transient Ischemic Attack Associated with Statin Treatment
Stroke 44:2814-2820, Merwick, A.,et al, 2013

Adult Attention Deficit - Hyperactivity Disorder
NEJM 369:1935-1944, Volkow, N.D. & Swanson, J.M., 2013

Faxtor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 44:e165-e167, Bruins, K.M.H., & Berge, E., 2013

Edoxaban Versus Warfarin in Patients with Atrial Fibrillation
NEJM 369:2093-2104, Giugliano, R.P.,et al, 2013



Showing articles 200 to 250 of 865 << Previous Next >>